Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip, bringing the concept of "smart-pill" technology a step closer.
The initial programme will use one of the Swiss firm's established transplant immunosuppression drugs. But Trevor Mundel, global head of development, believes the concept can be applied to many other pills.
"We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the regulators, at least in Europe," Mundel said.
"I see the promise as going much beyond that," he added.
Novartis agreed in January to spend $24 million to secure access to chip-in-a-pill technology developed by privately owned Proteus Biomedical of Redwood City, California, putting it ahead of rivals.
The ingestible chips are activated by stomach acid and send information on vital signs and compliance to a small patch worn on the patient's skin, which can transmit data to a smartphone or send it over the Internet to a doctor.
Mundel said the initial project was focused on ensuring that patients took drugs at the right time and got the correct dose.
Longer term, he hopes to expand the "smart pill" concept to other types of medicine and use the wealth of biometric information the Proteus chip can collect, from heart rate and temperature to body movement, to check that drugs are working properly.
Added to existing drugs
Because the tiny chips are added to existing drugs, Novartis doesn't expect to have to conduct full-scale clinical trials to prove the new products work. Instead, it aims to do bioequivalence tests.
A bigger issue may be what checks should be put in place to protect patients' personal medical data as it's transmitted from inside their bodies by wireless and Bluetooth.
"The regulators all like the concept and have been very encouraging. But they want to understand how we are going to solve the data privacy issues," Mundel said.
A technology that ensures a patient takes his or her medicine and checks that it is working properly should deliver better outcomes and justify a higher price tag.(Reuters Health/ November 2010)